Alkem Q2FY27: consolidated PAT falls 14% YoY to ₹667 Cr as tax rate resets higher
PAT -14.38% YoY · revenue +13.77% · margins compressing · beat vs street
₹4,551.99 Cr
+13.77% YoY
₹667.13 Cr
-14.38% YoY
14.24%
-4.7pp YoY
₹56.48
Alkem Laboratories posted consolidated revenue of ₹4,551.99 Cr for Q2 FY27, up 13.77% YoY (and 21.71% QoQ, though the sequential jump isn't fully comparable since Occlutech was consolidated only from 16 July 2026, partway through the prior quarter). Consolidated PAT (profit for the period) fell 14.38% YoY to ₹667.13 Cr; adjusted for a ₹35 Cr one-off investment-recovery gain booked this quarter with no counterpart a year ago, the decline widens to roughly 18.9%. Standalone (parent-only) PAT from continuing operations was ₹762.48 Cr, essentially flat YoY (+5.4% raw, ~+0.5% on the same adjusted basis) — so the consolidated decline is predominantly a tax and subsidiary-loss story rather than a core-business one. Consolidated EPS was ₹56.48 against ₹63.99 a year ago; standalone EPS was ₹63.77.
Q2 FY-2027 vs prior quarters
The operating margin held up better than feared: OPM (EBITDA/revenue) was 22.52% versus a tough 23.01% year-ago base and up from 20.48% in Q1 FY27, clearing management's reiterated FY27 guidance band of 20-21% despite a pre-result warning about paracetamol-API cost inflation roughly doubling input costs. Net margin fell much more sharply, from 18.98% to 14.24% YoY, because the effective tax rate jumped to 33.2% this quarter (32.9% for H1) from an unusually low ~13% a year ago, as the group completes its transition to the Section 115BAA tax regime — broadly consistent with management's own revised FY27 consolidated tax guidance of 30-32% (down from an earlier 35-38% flagged pre-result). By segment, core Pharmaceuticals EBIT grew 26.3% YoY to ₹1,051.88 Cr on revenue of ₹4,347.92 Cr (+11.8%), but Biotech swung to a ₹114.14 Cr loss (from a near-breakeven ₹0.35 Cr) and MedTech's loss widened to ₹49.63 Cr (from ₹6.31 Cr) as Occlutech — bought for a ~₹1,079.76 Cr consideration and adding ₹703.6 Cr of goodwill — had its first near-complete consolidated quarter; NCI absorbed ₹8.21 Cr of the group loss.
The stock went into the print at ₹5,241, down 0.2% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
India FY27 ~12% growth (100 bps above market); US mid-to-high single digit, forex-aided; Int'l sustainable double-digit; CDMO breakeven USD 25-30M annualized by FY28; Occlutech ₹400 Cr sales in 8.5 months, 7-8% EBITDA improvement YoY.
— This quarter: met
No public analyst consensus for PAT or revenue was available pre-result, so a direct beat/miss call on the bottom line isn't possible; against the one concrete, checkable pre-result benchmark — the 20-21% FY27 EBITDA-margin band flagged as the quarter's 'central test' amid API inflation and a high year-ago base — the 22.52% print is a beat. The same preview flagged the Daman facility's USFDA OAI status (affecting ~45% of US revenue) as unresolved; separately, the company disclosed on 30 October 2026 that a different API facility inspection closed with zero US FDA observations, an incremental positive that doesn't resolve Daman itself. No company press release/management commentary had been extracted for this filing at the time of this analysis, so framing here draws on the regulatory filing, segment notes and the pre-result analyst preview. The quarter also carried board-approved CEO succession (Dr. Amrut Naik, effective 11 November 2026, his first results call), a new Saudi Arabia JV, and a forensic audit initiated 21 October 2026 over alleged fund misappropriation — none of which register as quantified P&L items in this statement.
W1
FY27 EBITDA margin trajectory vs management's 20-21% guided band (Q2: 22.52%, Q1: 20.48%) amid flagged paracetamol-API cost inflation
W2
FY27 consolidated effective tax rate vs management's revised 30-32% guidance (H1 actual: 32.9%, Q2: 33.2%)
W3
Daman facility USFDA OAI resolution, flagged pre-result as affecting ~45% of US revenue, still unresolved as of this filing (a separate API facility inspection on 30-Oct-2026 closed with zero observations)
Figures in ₹ Million in source (÷10 to Cr); consolidated PAT (₹667.13 Cr, 'profit for the period') includes NCI drag from newly-consolidated Occlutech (55% stake, acquired 16-Jul-2026, loss-making) and a Biotech swing to loss, while owners'-share PAT is higher at ₹675.34 Cr; standalone PAT is continuing-operations only (no discontinued ops this quarter, unlike year-ago which had the then-recent Generic-business transfer); a ₹35 Cr exceptional gain (investment recovery) appears in both statements this quarter only, with none in the year-ago quarter; consolidated PBT−tax leaves a ₹0.6 Cr gap matching the share of associate loss, standalone ties out exactly.
Alkem Labs: Domestic Momentum & Margin Reset After Q1 Tax Drag
The Street awaits Q2 after a 22% profit drop in Q1 obscured strong 11% revenue growth. With mid-to-high single-digit US guidance intact and India outperforming the market by 100bps, the quarter should restore profit growth—but a CEO transition and legacy FDA issues on the filing stack warrant close watching.
What to Expect
~₹3,800–3,900 Cr
On-plan 11% run-rate from Q1; India +10%, intl +16% momentum intact
~₹650–700 Cr
Tax normalization from Q1's -22% drag; PBT tracking steadily
~10–11% YoY
IQVIA: Alkem 13.2% vs market 12.2% — 100bps outperformance to sustain
Mid-to-high single-digit growth
Q1 showed 16% YoY intl growth; guidance reiterated on calls
A strong print would see revenue holding ₹3,850+ Cr with India volume momentum intact (chronic +17.9%, acute +12.3% in Q1) and PAT hitting ₹680+ Cr as profit margins normalize post-tax reset. A weak print would flag slower domestic uptake below 10%, intl sales missing guidance or margin pressure pushing PAT below ₹640 Cr — either signalling execution slippage or softer end-market demand.
On Track to Guidance?
Alkem's FY27 outlook calls for double-digit revenue growth and margin expansion, with mid-to-high single-digit US growth. Q1 delivered 11% revenue growth; intl showed strength (+16%), and domestic outperformed the market. Q2 should confirm the run-rate holds. Management has flagged ongoing capex (₹75 Cr Baddi expansion approved Aug 14) and investments in CDMO and MedTech—near-term margin pressure risk if material. No full-year guidance revision has been signalled; trajectory appears on-plan, but the CEO transition and forensic audit may prompt commentary.
What the Street Says
Since Last Quarter: What Changed
1 · CEO Transition (Nov 3, 2026)
Dr. Amrut Naik appointed as new CEO and KMP, effective immediately. No prior tenure detail disclosed; Board cited Board performance as basis. This mid-quarter change could signal strategic shift—watch for guidance commentary on the call.
2 · Forensic Audit Underway (Oct 21, 2026)
Audit Committee approved Grant Thornton Bharat to investigate alleged misappropriation of funds by a former employee. Outcome TBD. This is a compliance/governance matter, not operational, but material if findings are adverse or quantitatively significant.
3 · FDA Observations Cleared (Oct 30, 2026)
Mandva API facility cleared after US FDA inspection (no observations). This is routine positive, but context: Amaliya facility (Aug 6) received OAI status after earlier inspection (Form FDA 483 noted 7 observations). Legacy regulatory cloud persists on Amaliya; Mandva clear is incremental good news.
4 · New Product Launches
NeuCeno (cenobamate, anti-seizure medication, Sep 16) and Renocia Exo hair serum (Sep 8) launched. Modest near-term revenue impact expected, but category expansion signals—chronic segment momentum evident in Q1 (+17.9% YoY).
5 · Capex & CDMO Expansion (Aug 14)
₹75 Cr capex approved for Baddi facility new block. CDMO and MedTech investments ongoing as per guidance. Near-term margin headwind possible, but strategic positioning for scale.
6 · Institutional Buying: HDFC MF, ICICI MF, DSP MF (Aug–Sep, 2026)
Multiple bulk/block buys around ₹5,200 by large MFs. Promoter (Samprada, Jayanti Sinha) saw selling on same rounds at ₹5,200. Net: institutional accumulation vs. some insider trimming. MF action suggests Street confidence; insider trim is noise at this valuation.
The Setup
Alkem Labs sits at an inflection: Q1's 11% revenue growth and market outperformance (100bps) signal execution strength in domestic pharma and international sales; PAT's 22% YoY drop was a tax artifact, not fundamental slippage. The Street expects steady-state profit recovery in Q2 (consensus ₹58.65 EPS). But the board is in flux—a new CEO, a forensic audit into fund misappropriation, and a legacy FDA flag on Amaliya all landed in the filing queue since Q1. FY27 guidance (double-digit growth, margin expansion, mid-high single-digit US) remains on the table, but credibility rides on clear execution on the call.
Three Things to Watch on Result Day
1 · Domestic momentum hold?
Did Q1's 10.3% India growth and market outperformance persist? A dip below 10% or failure to beat IPM growth would flag demand slowdown. Chronic segment strength (+17.9% in Q1) key to watch.
2 · PAT recovery & margin trajectory
Consensus expects ~₹58.65 EPS (vs. Q1's ~₹55.5). Any margin compression vs. PBT (Q1 was flat YoY) would surprise markets. Capex run-rate and CDMO investments commentary critical.
3 · Management commentary on CEO transition & forensic audit
How does new CEO frame strategy? What's the forensic audit timeline and expected financial impact? Any guidance revision or strategic shift disclosed here will reprrice the stock.
Alkem Labs reports Q2 FY27 unaudited results on November 12, 2026. The Street expects steady-state profit recovery after Q1's tax drag, anchored by domestic pharma momentum and international sales tracking guidance. But governance shadows—a CEO transition, a forensic audit, and a legacy FDA flag—mean execution will be scrutinized closely. Revenue trajectory and PAT guidance credibility are the print, but investor sentiment will hinge as much on management's tone on the audit and strategy.